Your search for "" returned the following 530 results.
Solange Peters, M.D., Ph.D.
Dr. Solange Peters is a Professor and Head of Medical Oncology and Thoracic Malignancies at the Department of Oncology at Lausanne University, Switzerland, where she is also building a translational program in collaboration with molecular oncology laboratories. Dr. Peters was the President of the European Society for Medical Oncology (ESMO) 2020-22, and was formerly an IASLC Board member and co-chair of the Swiss…Read More
BerGenBio ASA: Invitation to fourth quarter 2022 results webcast
Bergen, Norway, 1 February 2023 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the fourth quarter 2022 on Thursday 16 February 2023. The briefing will take place at 10:00 am CET at:Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslowhere BerGenBio's senior management team will…Read More
Clinical Scientist, Oxford
We are currently recruiting for a Clinical Scientist to work as a core part of the clinical development team within BerGenBio, supporting with oncology studies and with pharmacovigilance activities as required. BerGenBio is a clinical-stage biopharmaceutical company focused on developing innovative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. We offer…Read More
Nordic Healthcare Conference 2022, 15 December 2022
15 December 2022Read More
Quality Assurance Manager, Oxford
Are you a Quality Assurance professional working in drug development? Would you be interested in a fast-paced and wide-ranging role with opportunities for progression? BerGenBio is a clinical-stage biopharmaceutical company focused on developing innovative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. We are looking to recruit a Quality Assurance Manager…Read More
BerGenBio Reports Third Quarter 2022 Financial Results and Provides Business Update
- Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients -- Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 mutations -- Strengthened financial position with support from largest shareholder - BERGEN, Norway, November 15, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet…Read More